Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma

TGF-β2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication

25-Jul-2012 - Germany

Antisense Pharma GmbH announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational oncology antisense compound trabedersen to treat malignant melanoma.

Previously, trabedersen has received Orphan Drug designation by the European EMA and the US FDA in high-grade glioma (malignant brain tumor) in 2002 and in advanced pancreatic cancer in 2009.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances